Tech Company Financing Transactions

Allakos Funding Round

On 12/18/2012, Allakos secured $32 million in Series A funding from Novo Ventures, Alta Partners and RiverVest Venture Partners.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

975 Island Dr. 201
Redwood City, CA 94065
USA

Phone

(650) 597-5002

Website

www.allakos.com

Email Address

[email protected]

Overview

Allakos (Nasdaq: ALLK) is a biotechnology company developing antibodies targeting receptors that modulate the activity of immune effector cells involved in inflammation and tissue damage.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Robert Alexander

        

Chief Medical Officer

Henrik Rasmussen

        

Chief Operating Officer

Adam Tomasi

        

VP - Bus. Development

Simon Greenwood

        

VP - General Counsel

Mark Asbury

        

VP - Regulatory Affairs

Sally Bolmer

        

Browse more venture capital transactions:

Prev: 12/18/2012: Ortho Kinematics venture capital transaction
Next: 12/18/2012: Compass RE venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary